Canlyniadau Chwilio - Mathias Witzens‐Harig

  • Dangos 1 - 19 canlyniadau o 19
Mireinio'r Canlyniadau
  1. 1
    T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy

    T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy gan Angela M. Krackhardt, Sabine Harig, Mathias Witzens‐Harig, Ryan Broderick, Patrick Barrett, John G. Gribben

    Cyhoeddwyd 2002
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation

    Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation gan Patrick Wuchter, Dan Ran, Thomas Brückner, Thomas Schmitt, Mathias Witzens‐Harig, Kai Neben, Hartmut Goldschmidt, Anthony D. Ho

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells

    Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells gan Nathalie Fiegler, Sonja Textor, Annette Arnold, Alexander Rölle, Ina Oehme, Kai Breuhahn, Gerhard Moldenhauer, Mathias Witzens‐Harig, Adelheid Cerwenka

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX

    Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX gan Angela M. Krackhardt, Mathias Witzens‐Harig, Sabine Harig, F. Stephen Hodi, A. Jason Zauls, Morgan Chessia, Patrick Barrett, John G. Gribben

    Cyhoeddwyd 2002
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma

    Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma gan Carmen Choi, Mathias Witzens‐Harig, Marianna Bucur, Markus Feuerer, Nora Sommerfeldt, Andreas Trojan, Anthony D. Ho, Volker Schirrmacher, Hartmut Goldschmidt, Philipp Beckhove

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials

    Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials gan Liat Vidal, Anat Gafter‐Gvili, Gilles Salles, Martin Dreyling, Michele Ghielmini, Shu‐Fang Hsu Schmitz, Ruth Pettengell, Mathias Witzens‐Harig, Ofer Shpilberg

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells

    The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells gan Sonja Textor, Felicitas Bossler, Kai-Oliver Henrich, Moritz Gartlgruber, Julia Pollmann, Nathalie Fiegler, Annette Arnold, Frank Westermann, Nina Waldburger, Kai Breuhahn, Sven Golfier, Mathias Witzens‐Harig, Adelheid Cerwenka

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL gan Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, Viola Poeschel, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Christian Schmidt, Michael Hallek, Mathias Witzens‐Harig, Lorenz Trümper, Torben Rixecker, C. Zwick

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement

    Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement gan Gerhard Held, Samira Zeynalova, Niels Murawski, Marita Ziepert, B. Kempf, Andreas Viardot, Martin Dreyling, Michael Hallek, Mathias Witzens‐Harig, Jochen Fleckenstein, Christian Rübe, Carsten Zwick, Bertram Glaß, Norbert Schmitz, Michael Pfreundschuh

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

    Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma gan Georg Heß, Ulrich Keller, Christian W. Scholz, Mathias Witzens‐Harig, J. Atta, Christian Buske, Sebastian Kirschey, Christian Ruckes, Christoph Medler, C. van der Houven van Oordt, Wolfram Klapper, Matthias Theobald, M. Dreyling

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

    Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study gan Mathias Witzens‐Harig, Robin Foà, Alice Di Rocco, Guy van Hazel, Dalton F. Chamone, Jacob M. Rowe, Luca Arcaini, I V Poddubnaya, Anthony D. Ho, Valentina Ivanova, Andrej Vranovský, Dan Thurley, Stephan Oertel

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Errata/Corrigenda
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

    Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgk... gan Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Martin Dreyling, Michael Hallek, Carsten Mueller, Martin H. J. Wiesen, Mathias Witzens‐Harig, Lorenz Truemper, Ulrich Keller, Tanja Rixecker, Carsten Zwick, Niels Murawski

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study gan Simon Rule, Wojciech Jurczak, Mats Jerkeman, C. Rusconi, Marek Trněný, Fritz Offner, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Georg Heß, Isabelle Bence‐Bruckler, Seok‐Goo Cho, Catherine Thiéblemont, Wangchi Zhou, Todd Henninger, Judith D. Goldberg, Jessica Vermeulen, Martin Dreyling

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY

    IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY gan Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Alves da Silva, C. Rusconi, Marek Trněný, Fritz Offner, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Georg Heß, I. Bence‐Bruckler, S. Cho, Catherine Thiéblemont, Wangchi Zhou, Todd Henninger, Jeffrey L. Goldberg, Jessica Vermeulen, Martin Dreyling

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Rituximab With Involved Field Irradiation for Early‐stage Nodal Follicular Lymphoma

    Rituximab With Involved Field Irradiation for Early‐stage Nodal Follicular Lymphoma gan Klaus Herfarth, Peter Borchmann, Sven Schnaidt, Karin Hohloch, Volker Budach, M. Engelhard, Andreas Viardot, Rita Engenhart‐Cabillic, Ulrich Keller, Gabriele Reinartz, Hans‐Theodor Eich, Mathias Witzens‐Harig, Clemens F. Hess, Bernd Dörken, Jan Dürig, Thomas Wiegel, Wolfgang Hiddemann, Eva Hoster, Christiane Pott, Martin Dreyling

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer

    Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer gan Mark Kriegsmann, Christian Haag, Cleo‐Aron Weis, Georg Steinbuß, Arne Warth, Christiane Zgorzelski, Thomas Muley, H. Winter, Martin Eichhorn, Florian Eichhorn, Joerg Kriegsmann, Petros Christopoulos, Michael Thomas, Mathias Witzens‐Harig, Hans‐Peter Sinn, Moritz von Winterfeld, Claus Peter Heußel, Felix J.F. Herth, Frederick Klauschen, Albrecht Stenzinger, Katharina Kriegsmann

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

    Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study gan Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trněný, Fritz Offner, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Georg Heß, Isabelle Bence‐Bruckler, Seok‐Goo Cho, John Bothos, Jeffrey L. Goldberg, Christopher Enny, Shana Traina, Sriram Balasubramanian, Nibedita Bandyopadhyay, Steven Sun, Jessica Vermeulen, Aleksandra Rizo, Simon Rule

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

    The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma gan Niels Weinhold, David C. Johnson, Daniel Chubb, Bowang Chen, Asta Försti, Fay J. Hosking, Peter Broderick, P. Yussanne, Sara E. Dobbins, Dirk Hose, Brian A. Walker, Faith E. Davies, Martin Kaiser, Ni L Li, Walter A. Gregory, Graham Jackson, Mathias Witzens‐Harig, Kai Neben, Per Hoffmann, Markus M. Nöthen, Thomas W. Mühleisen, Lewin Eisele, Fiona M. Ross, Anna Jauch, Hartmut Goldschmidt, Richard S. Houlston, Gareth J. Morgan, Kari Hemminki

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

    Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a rando... gan Viola Poeschel, Gerhard Held, Marita Ziepert, Mathias Witzens‐Harig, Harald Holte, Lorenz Thurner, Peter Borchmann, Andreas Viardot, Martin Soekler, Ulrich Keller, Christian Schmidt, Lorenz Truemper, Rolf Mahlberg, Reinhard Marks, Heinz‐Gert Hoeffkes, Bernd Metzner, Judith Dierlamm, Norbert Frickhofen, Mathias Haenel, Andreas Neubauer, Michael Kneba, Francesco Merli, Alessandra Tucci, Peter de Nully Brown, Massimo Federico, Eva Lengfelder, Alice Di Rocco, Ralf Ulrich Trappe, Andreas Rosenwald, Christian Berdel, Martin Maisenhoelder, Ofer Shpilberg, Josif Amam, Konstantinos Christofyllakis, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Maike Nickelsen, Gerald Wulf, Bertram Glaß, Norbert Schmitz, Bettina Altmann, Markus Loeffler, Michael Pfreundschuh

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: